Sinovac Biotech Slips To Loss In Q2 - Quick Facts

(RTTNews) - Sinovac Biotech Ltd. (SVA) reported second-quarter net loss attributable to common stockholders of $2.2 million, or $0.04 per share, compared to a net income attributable to common stockholders of $1.3 million, or $0.02 per share, in the comparable quarter last year.

Two analysts polled by Thomson Reuters expected the company to report $0.00 per share for the quarter.

Total sales for the latest second-quarter were $12.1 million, down 30.7% from $17.5 million in the prior year quarter. This decrease was primarily due to softer demand in the private vaccine market.